

(All amounts in Indian Rupees in Lakhs, unless otherwise stated)

		STANDALONE					
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 months ended		For the year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
		Un-Audited	Un-Audited	Audited	Un-Audited	Audited	Audited
1	Income	(1)	(2)	(3)	(4)	(5)	(6)
	Revenue from operations	23,738.81	23,823.24	27,292.76	47,562.05	47,031.90	83,378.97
	Other Income	35.68	573.91	544.52	609.59	788.98	1,811.73
	Total income	23,774.49	24,397.15	27,837.28	48,171.64	47,820.88	85,190.70
2	Expenses						
	a) Cost of materials consumed	7,717.95	6,600.27	6,047.63	14,318.22	11,913.94	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(355.65)	474.64	3,057.82	118.99	1,325.68	(1,105.44)
	d) Employee benefits expense	2,092.90	1,744.42	1,525.79	3,837.32	3,230.66	6,510.44
	e) R & D expense	381.42	307.85	529.43	689.27	803.21	1,413.14
	f) Finance costs	326.29	320.62	399.11	646.91	743.33	2,181.26
	g) Depreciation and amortisation expenses	750.02	706.34	553.45	1,456.36	1,103.18	2,350.69
	h) Manufacturing Expenses	2,970.64	2,388.71	2,646.22	5,359.35	5,141.32	10,384.42
	i) Other Expenses	1,082.22	1,096.61	937.32	2,178.83	1,821.70	3,672.81
	Total expenses	14,965.79	13,639.46	15,696.77	28,605.25	26,083.02	49,431.67
3	Profit before exceptional items & Tax (1-2)	8,808.70	10,757.69	12,140.51	19,566.39	21,737.86	35,759.03
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	8,808.70	10,757.69	12,140.51	19,566.39	21,737.86	35,759.03
6	Tax Expenses						
	a) Current tax	2,163.92	2,728.72	3,140.18	4,892.64	5,569.60	8,880.94
	b) Deferred tax	111.78	(94.03)	8.75	17.75	(315.84)	(129.93)
7	Net Profit/ (Loss) for the period/ year(5-6)	6,533.00	8,123.00	8,991.58	14,656.00	16,484.10	27,008.02
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(27.32)	(27.33)	(4.23)	(54.65)	(8.46)	(109.31)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.88	6.88	1.48	13.76	2.96	27.51
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(20.44)	(20.45)	(2.75)	(40.89)	(5.50)	(81.80)
9	Total Comprehensive Income for the period (7+8)	6,512.56	8,102.55	8,988.83	14,615.11	16,478.60	26,926.22
10	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	2,545.65 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
11	Other Equity						77,010.16
12	Earning Per Share (EPS)- Restated, ref note No: 4 (Face value of Rs.1/- each) :						
	a) Basic	2.57	3.19	3.53	5.76	6.48	10.61
	b) Diluted	2.57	3.19	3.53	5.76	6.48	10.61
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

CONSOLIDATED							
<i>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</i>							
Sl. No.	PARTICULARS	For the Quarter Ended			For the 6 months ended		For the year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
		Un-Audited	Un-Audited	Audited	Un-Audited	Audited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	
1	Income						
	Revenue from operations	23,738.81	23,823.24	27,292.76	47,562.05	47,031.90	83,378.97
	Other Income	35.68	573.91	544.52	609.59	788.98	1,811.73
	Total income	23,774.49	24,397.15	27,837.28	48,171.64	47,820.88	85,190.70
2	Expenses						
	a) Cost of materials consumed	7,717.95	6,600.27	6,047.63	14,318.22	11,913.94	24,024.35
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(355.65)	474.64	3,057.82	118.99	1,325.68	(1,105.45)
	d) Employee benefits expense	2,092.90	1,744.42	1,525.79	3,837.32	3,230.66	6,510.44
	e) R & D expense	381.42	307.85	529.43	689.27	803.21	1,413.15
	e) Finance costs	326.29	320.62	442.40	646.91	824.30	2,306.60
	f) Depreciation and amortisation	750.02	706.34	553.45	1,456.36	1,103.18	2,350.69
	g) Manufacturing Expenses	2,970.64	2,388.71	2,646.22	5,359.35	5,141.32	10,384.42
	h) Other Expenses	1,082.58	1,099.21	937.31	2,181.79	1,822.73	3,676.58
	Total expenses	14,966.15	13,642.06	15,740.05	28,608.21	26,165.02	49,560.78
3	Profit before exceptional items, Tax & share in profit/ (Loss) of Associates (1-2)	8,808.34	10,755.09	12,097.23	19,563.43	21,655.86	35,629.92
4	Add: Share of profit/(Loss) of Associates	875.26	1,031.76	352.19	1,907.02	2,088.80	4,821.26
5	Profit before exceptional items, Tax (3+4)	9,683.60	11,786.85	12,449.42	21,470.45	23,744.66	40,451.18
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax (5-6)	9,683.60	11,786.85	12,449.42	21,470.45	23,744.66	40,451.18
8	Tax Expenses						
	a) Current tax	2,163.92	2,728.72	3,140.18	4,892.64	5,569.60	8,880.94
	b) Deferred tax	111.78	(94.03)	8.76	17.75	(315.84)	(129.93)
9	Net Profit/ (Loss) for the period/year(7-8)	7,407.90	9,152.16	9,300.48	16,560.06	18,490.90	31,700.17
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	(27.32)	(27.33)	(4.23)	(54.65)	(8.46)	(109.30)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.88	6.88	1.48	13.76	2.96	27.51
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(20.44)	(20.45)	(2.75)	(40.89)	(5.50)	(81.79)
11	Total Comprehensive Income for the period (9 + 10)	7,387.46	9,131.71	9,297.73	16,519.17	18,485.40	31,618.38
12	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00	2,545.65 Re.1.00	1,272.82 Re.1.00	1,272.82 Re.1.00
13	Other Equity						83,203.45
14	Earning Per Share (EPS)- Restated ,ref note No: 4 (Face value of Rs.1/- each) :						
	a) Basic	2.91	3.60	3.65	6.51	7.26	12.45
	b) Diluted	2.91	3.60	3.65	6.51	7.26	12.45
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

- Notes**
- 1) The above unaudited financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30th October, 2020. The above results have been subjected to limited review by the statutory auditors of the company.
 - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma Inc., and Associate Rising Pharma Holdings Inc.
 - 4) The Board has allotted the Bonus shares at 1:1 ratio in it's Board Meeting held on 29th Sept, 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated. The paid-up capital on account of Bonus issue of Rs.1272.82 lakhs has been appropriated from Share premium account.
 - 5) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 6) Consequent to the demerger of Contract Research and Manufacturing services (CRAMS) Undertaking of the erstwhile Suven Life Sciences Limited as a going concern into the Company, pursuant to the Scheme effective from appointed date being 1st October, 2018. The Suven Life Sciences Limited (SLSL/Demerged Company) has to transfer the statutory and regulatory licenses with in India and Outside India so as to enable the Company (SPL) to carry on the business in its name. The process of obtaining the approvals from all departments is a lengthy process. In order to maintain the continuity of the business during these statutory approvals period, the SLSL is continuing the CRAMS business in its own name on behalf of SPL. However, all such operations were recorded in the books of SPL, the same may be continued till the migration of all licenses in the name of SPL.
 - 7) The Board has approved CAPEX plan of INR 60,000 lakhs keeping in view of the proposed increase in capacity in Pashamylaram facility, replacement and modernization of old production blocks in Suryapet facility, relocation of R&D facilities from Jeedimetla and acquisition of new technologies.
 - 8) On 30 January' 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11 March' 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. During this period, the Company has experienced minor disruptions impacting our operations even though there were no major consequences which will materially affect the Company.
 - 9) Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other contents in building was damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the period ended Sept 30, 2020, the company has written-off net book value of assets aggregating Rs 109.30 Lakhs and recognised a minimum insurance claim receivable for equivalent amount .
 - 10) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD

Place : Hyderabad
Date : 30th October, 2020

VENKAT JASTI
Chairman & MD
DIN: 00278028

SUVEN PHARMACEUTICALS LIMITED		
Standalone Statement of Cash flows for the period ended 30th September, 2020		
<i>(All amounts in Indian Rupees in Lakhs, unless otherwise stated)</i>		
Particulars	For the period ended 30th September 2020	For the period ended 30th September 2019
A. Cash flow from operating activities	Un-Audited	Audited
Profit before tax	19,566.39	21,737.86
Adjustments :		
Depreciation and amortisation expense	1,439.72	1,120.73
Interest Income	(18.05)	(19.20)
Finance Cost	646.91	743.33
Gain on sale of Current Investment	(155.39)	(151.21)
Loss/(Profit) on disposal of Property, plant & equipment	-	(8.00)
Operating profit before working capital changes	21,479.58	23,423.51
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	1,165.24	(1,384.68)
Inventories	(2,261.60)	478.47
Other non current assets	819.47	(883.68)
Other current assets	(3,228.57)	(831.57)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	923.62	(709.47)
Other non-current liabilities	-	
Short term provision	223.34	95.54
Other financial liabilities	(615.60)	241.63
Other current liabilities	(130.78)	(184.62)
Cash generated from operating activities	18,374.69	20,245.13
Income taxes paid (net of refunds)	4,059.96	950.40
Net Cash flows from operating activities	14,314.73	19,294.73
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(6,284.76)	(2,974.49)
Proceeds from sale of Property, plant & equipment	-	21.43
Changes in Investments	-	(20,875.50)
Sale/(purchase) of mutual funds	(3,888.02)	(8,583.51)
Bank balances not considered as cash and cash equivalents	(199.84)	(2.40)
Net cash flow from /(used in) investing activities	(10,372.62)	(32,414.47)
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	(3,623.43)	-
(Repayment)/Proceeds from short term borrowings	275.93	18,317.28
Other non current financial assets	1.37	(10.19)
Other current financial assets	(9.29)	(21.67)
Finance Cost	(646.91)	(743.33)
Interest received	18.05	19.20
Changes In Lease Liability	94.64	-
Net cash flow from /(used In) financing activities	(3,889.63)	17,561.29
Net increase/(decrease) in cash and cash equivalents	52.48	4,441.55
Cash and cash equivalents as at the beginning of the year	1,157.68	1,090.30
Cash and cash equivalents at the end of the year	1,210.16	5,531.85
Cash and cash equivalents	1,210.16	5,531.85
Balances per statement of cash flows	1,210.16	5,531.85
For Suven Pharmaceuticals Ltd		
Place : Hyderabad	Venkat Jasti	
Date : 30th October, 2020	Chairman & MD	
	DIN: 00278028	

SUVEN PHARMACEUTICALS LIMITED		
Consolidated Statement of Cash flows for the period ended 30th September, 2020		
(All amounts in Indian Rupees In Lakhs, unless otherwise stated)		
Particulars	For the period ended 30th September 2020	For the period ended 30th September 2019
A. Cash flow from operating activities	Un-Audited	Audited
Profit before tax	21,470.45	21,655.86
Adjustments :		
Depreciation and amortisation expense	1,439.72	1,120.73
Interest Income	(18.05)	(19.20)
Finance Cost	646.91	824.30
Gain on sale of Current Investment	(155.39)	(151.21)
Loss/(Profit) on disposal of Property, plant & equipment	-	(8.00)
Operating profit before working capital changes	23,383.64	23,422.48
Adjustments for (Increase)/decrease in operating assets		
Trade Receivables	1,165.24	(1,384.68)
Inventories	(2,261.60)	478.47
Other non current assets	819.47	(883.68)
Other current assets	(3,228.57)	(831.57)
Adjustments for Increase/(decrease) in operating liabilities		
Trade Payables	923.62	(709.47)
Other non-current liabilities	-	
Short term provision	223.34	95.54
Other financial liabilities	(619.97)	325.74
Other current liabilities	(130.78)	(184.62)
Cash generated from operating activities	20,274.38	20,328.21
Income taxes paid (net of refunds)	4,059.96	950.40
Net Cash flows from operating activities	16,214.42	19,377.81
B. Cash flow from Investing activities		
Payments for Purchase of property, plant and equipment	(6,284.76)	(2,974.49)
Proceeds from sale of Property, plant & equipment	-	21.43
Changes in Investments	(1,907.02)	(24,675.00)
Sale/(purchase) of mutual funds	(3,888.02)	(8,583.51)
Foreign currency translation reserve	(0.14)	272.35
Bank balances not considered as cash and cash equivalents	(199.84)	(2.40)
Net cash flow from /(used in) investing activities	(12,279.79)	(35,941.62)
C. Cash flows from financing activities		
(Repayment)/Proceeds from long term borrowings	(3,623.43)	
(Repayment)/Proceeds from short term borrowings	275.93	21,842.28
Other non current financial assets	1.37	(10.19)
Other current financial assets	(9.29)	(4.04)
Finance Cost	(646.91)	(824.30)
Interest received	18.05	19.20
Changes In Lease Liability	94.64	
Net cash flow from /(used In) financing activities	(3,889.63)	21,022.95
Net increase/(decrease) in cash and cash equivalents	45.00	4,459.14
Cash and cash equivalents as at the beginning of the year	1,169.53	1,090.30
Cash and cash equivalents at the end of the year	1,214.53	5,549.44
Cash and cash equivalents	1,214.53	5,549.44
Balances per statement of cash flows	1,214.53	5,549.44

For Suven Pharmaceuticals Ltd

Venkat Jasti
Chairman & M D
DIN: 00278028

Place : Hyderabad
Date : 30th October, 2020

Statement of Assets & Liabilities

(All amounts in Indian Rupees In Lakhs, unless otherwise stated)

Particulars	Standalone as at		Consolidated as at	
	30/09/2020	31/03/2020	30/09/2020	31/03/2020
	Un-Audited	Audited	Un-Audited	Audited
A ASSETS				
1 Non-current assets				
(a) Property, Plant and Equipment	42,738.92	35,306.20	42,738.92	35,306.20
(b) Capital Work-in-Progress	7,492.94	10,170.52	7,492.94	10,170.52
(c) 1) Other Intangible Assets	260.18	279.59	260.18	279.59
2) Right of use of assets	177.87	88.58	177.87	88.58
(d) Financial Assets				
I. Investments	24,564.73	24,564.73	32,652.83	30,745.81
II. Loans	6.20	6.00	6.20	6.00
III. Other Financial Assets	473.02	474.59	473.02	474.59
(e) Deferred tax assets (net)	-	-	-	-
(f) Other non current assets	136.33	1,045.08	136.33	1,045.08
Total Non-Current assets	75,850.19	71,935.29	83,938.29	78,116.37
2 Current assets				
(a) Inventories	19,748.81	17,487.22	19,748.81	17,487.22
(b) Financial Assets				
I. Investments	7,110.74	3,067.33	7,110.74	3,067.33
II. Trade Receivables	10,554.34	11,719.58	10,554.34	11,719.58
III. Cash and Cash equivalents	1,210.16	1,157.68	1,214.53	1,169.53
IV. Bank balances other than (III) above	437.81	237.97	437.81	237.97
V. Loans	29.68	20.39	29.68	20.39
VI. Other Financial assets	0.28	0.28	0.28	0.28
(c) Current Tax asset (net)	-	-	-	-
(d) Other current assets	8,800.26	5,462.38	8,800.26	5,462.37
Total Current assets	47,892.08	39,152.83	47,896.45	39,164.67
TOTAL - ASSETS	123,742.27	111,088.12	131,834.74	117,281.04
B EQUITY AND LIABILITIES				
1 EQUITY				
(a) Equity Share Capital	2,545.65	1,272.82	2,545.65	1,272.82
(b) Other Equity	90,352.44	77,010.16	98,449.65	83,203.45
Equity attributable to owners of the company	92,898.09	78,282.98	100,995.30	84,476.27
2 LIABILITIES				
(a) Financial Liabilities				
I. Lease Liability	96.63	51.19	96.63	51.19
II. Borrowings	5,501.81	9,125.25	5,501.81	9,125.25
(b) Provisions	831.46	831.46	831.46	831.46
(c) Deferred tax Liabilities (net)	2,763.72	2,759.72	2,763.72	2,759.72
(d) Other non current liabilities	-	-	-	-
Total non-current liabilities	9,193.62	12,767.62	9,193.62	12,767.62
Current liabilities				
(a) Financial Liabilities				
I. Lease Liability	89.61	40.41	89.61	40.41
II. Borrowings	9,679.73	9,403.80	9,679.73	9,403.80
III. Trade payables				
a) To Micro & Small Enterprises	40.58	263.13	40.58	263.13
b) Other than Micro & Small Enterprises	7,988.58	6,842.44	7,988.58	6,842.44
IV. Other Financial Liabilities	1,704.29	2,319.89	1,699.55	2,319.52
(b) Current Tax liabilities (Net)	1,358.07	525.36	1,358.07	525.36
(c) Other Current liabilities	260.06	390.84	260.06	390.84
(d) Provision Employee benefits	529.64	251.65	529.64	251.65
Sub-total - Current liabilities	21,650.56	20,037.52	21,645.82	20,037.15
Total Liabilities	30,844.18	32,805.14	30,839.44	32,804.77
TOTAL - EQUITY AND LIABILITIES	123,742.27	111,088.12	131,834.74	117,281.04

For Suvan Pharmaceuticals Ltd

Place : Hyderabad
Date: 30th October, 2020

Venkat Jasti
Chairman & MD